Narrative review discusses TIVAP use in Chinese patients requiring long-term venous therapyReport finds uneven standards for venous access ports in China

This narrative review focuses on the clinical application of Totally Implantable Venous Access Ports (TIVAP) specifically within the Chinese healthcare setting. The scope encompasses patients requiring long-term venous therapy, including those in oncology and other groups. The authors do not report specific sample sizes, primary outcomes, or adverse event rates, as these details were not reported in the source material.

The authors synthesize the current landscape by identifying critical structural gaps. They note that China lacks a unified regulatory framework and standardized full-lifecycle management protocols for these devices. Furthermore, significant disparities exist among medical institutions concerning surgical techniques, complication management, and surveillance capabilities. These factors collectively influence the safety and efficacy landscape for TIVAP usage.

Despite the absence of reported safety data or specific outcome statistics, the review offers a comprehensive reference for optimizing clinical decision-making. The authors suggest that addressing these systemic issues is essential for minimizing adverse events and improving patient quality of life. Clinicians should interpret these findings with caution given the lack of quantitative data and the acknowledged regulatory and procedural inconsistencies.